Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| BRAF inhibitor | BRAF inhibitor is a B-Raf inhibitor with anti-tumor activity extracted from patent WO/2011103196 A1, Compound P-0850. Uses: Scientific research. Group: Signaling pathways. CAS No. 918505-61-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-10247. |  |
| 1, 1, 1-Trifluoromethane sulfonic Acid Tris(1-methylethyl)silyl Ester | 1, 1, 1-Trifluoromethane sulfonic Acid Tris(1-methylethyl)silyl Ester is used in the synthesis of potent BRAF kinase inhibitors used in the therapeutic treatment of melanoma. Also used in the synthesis of antitumor antibiotic (+)-FR900482. Group: Biochemicals. Alternative Names: TIPSOTf; Triisopropyl (trifluoromethane sulfonato) silane ; Triisopropylsilyl Triflate; Triisopropylsilyl Trifluoromethane sulfonate. Grades: Highly Purified. CAS No. 80522-42-5. Pack Sizes: 5g. US Biological Life Sciences. |  Worldwide |
| 2, 6-Difluoro Benzene sulfonyl Chloride | 2, 6-Difluoro Benzene sulfonyl chloride is used as a reagent to synthesize Dabrafenib, an inhibitor of BRAF kinase that is used to treat BRAF V600-mutation positive carcinoma. BRAF is a gene that mediates cell growth and is activated by mutations caused by cancer. 2, 6-Difluoro Benzene sulfonyl chloride is also a potential inhibitor of zinc proteases. Group: Biochemicals. Grades: Highly Purified. CAS No. 60230-36-6. Pack Sizes: 5g, 10g. Molecular Formula: C6H3ClF2O2S, Molecular Weight: 212.6. US Biological Life Sciences. | Worldwide |
| 3-Amino-4-fluorophenylboronic Acid Pinacol Ester | 3-Amino-4-fluorophenylboronic Acid Pinacol Ester is used as a reactant in preparation of LY3009120 as pan-RAF inhibitor with activity against BRAF or RAS mutant tumor cells. Group: Biochemicals. Grades: Highly Purified. CAS No. 1003575-43-6. Pack Sizes: 100mg, 250mg. Molecular Formula: C12H17BFNO2, Molecular Weight: 237.08. US Biological Life Sciences. | Worldwide |
| AD57 | AD57 is a multikinase inhibitor that inhibits RET, BRAF, S6K and Src. It is used in cancer therapeutic. Synonyms: 1-(4-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea. Grades: >98.0%. CAS No. 1093380-42-7. Molecular formula: C22H20F3N7O. Mole weight: 455.45. |  |
| AD57 | AD57 is an orally active multikinase inhibitor, inhibits RET , BRAF , S6K and Src , with greatly reduces mTOR activity [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1093380-42-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg. Product ID: HY-18507. | |
| AD80 | AD80, also called as A-196, is a multikinase inhibitor that inhibits against human BRAF, S6K, and SRC and shows strong activity against RET inhibitor. Synonyms: 1-[4-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)phenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea; AD80; AD-80; AD 80; s8518. CAS No. 1384071-99-1. Molecular formula: C22H19F4N7O. Mole weight: 473.43. | |
| Agerafenib | Agerafenib (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of BRAFV600E with a Kd of 14 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CEP-32496; RXDX-105. CAS No. 1188910-76-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15200. | |
| ARQ 736 | ARQ 736 is a potent and selective BRAF inhibitor. ARQ 736 is selectively potent in killing cancer cell lines harboring at least one mutated BRAF allele. BRAF mutations were detected in over 60% of melanomas and may account for a significant proportion of colon cancer patients whose tumors are resistant to anti-EGFR therapy. Synonyms: ARQ 736; ARQ736; ARQ-736. CAS No. 1228237-47-5. Molecular formula: C25H25N8Na2O8PS. Mole weight: 630.569. | |
| ASTX-029 | ASTX029 is a highly potent and selective dual-mechanism ERK inhibitor. ASTX029 inhibits both ERK catalytic activity and the phosphorylation of ERK itself by MEK, despite not directly inhibiting MEK activity. ASTX029 preferentially inhibited the proliferation of MAPK-activated cell lines, including those with BRAF or RAS mutations. ASTX029 also demonstrated activity in both in vitro and in vivo models of acquired resistance to MAPK pathway inhibitors. Uses: Designed for use in research and industrial production. Additional or Alternative Names: ASTX-029; ASTX029; ASTX 029. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 2095719-92-7. Molecular formula: C29H31ClFN5O5. Mole weight: 584.05. Purity: >98%. IUPACName: (R)-2-(6-(5-chloro-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1-oxoisoindolin-2-yl)-N-((S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)propanamide. Canonical SMILES: ClC(C(C1=CC=C2C(C(N([C@H](C)C(N[C@H](CO)C3=CC(OC)=CC(F)=C3)=O)C2)=O)=C1)=N4)=CN=C4NC5CCOCC5. Product ID: ACM2095719927. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Avutometinib | Avutometinib (Ro 5126766) is a first-in-class dual MEK / RAF inhibitor that allosterically inhibits BRAF V600E , CRAF , MEK , and BRAF (IC 50 : 8.2, 56, 160 nM, and 190 nM, respectively). Uses: Scientific research. Group: Signaling pathways. Alternative Names: Ro 5126766; CH5126766. CAS No. 946128-88-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18652. | |
| AZ304 | AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC 50 s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 ( IC 50 , 6 nM), CSF1R ( IC 50 , 35 nM). Anti-tumor activity [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 942507-42-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-117273. | |
| AZ304 | AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 with IC50 of 6 nM, CSF1R with IC50 of 35 nM. It shows antitumor activity. Synonyms: AZ-304; AZ 304. Grades: ≥98%. CAS No. 942507-42-8. Molecular formula: C27H25N5O2. Mole weight: 451.52. | |
| BI-882370 | BI-882370 is a highly potent, selective, orally active RAF inhibitor with IC50 of 0.4, 0.8 and 0.6 nM for BRAF V600E, BRAF WT and CRAF, respectively. BI-882370 is a potent and selective RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. BI-882370 inhibits proliferation of human BRAF-mutant melanoma cells with 100× higher potency (1-10 nmol/L) than vemurafenib. BI-882370 may provide an improved therapeutic window, enabling more pronounced and longer-lasting pathway suppression and thus resulting in improved efficacy. Synonyms: BI882370; BI 882370. Grades: ≥95%. CAS No. 1392429-79-6. Molecular formula: C28H33F2N7O2S. Mole weight: 569.7. | |
| Braftide | Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAF G469A with IC 50 of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells ( EC 50 is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence [1]. Uses: Scientific research. Group: Peptides. CAS No. 2411851-64-2. Pack Sizes: 5 mg; 10 mg. Product ID: HY-P10436. | |
| CCT196969 | This active molecular is a novel , paradox-breaking pan-RAF inhibitor with anti-SRC activity and it blocked growth of BRAF-mutant and NRAS-mutant melanoma cells, inhibiting MEK -ERK. CCT196969 also prevented growth of xenografts derived from patient tumours with resistance to BRAF and MEK inhibitors. Uses: Effective in drug-resistant braf mutant melanoma. Synonyms: CCT196969; CCT-196969; CCT 196969. N-[4-[(3,4-Dihydro-3-oxopyrido[2,3-b]pyrazin-8-yl)oxy]-2-fluorophenyl]-N'-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]urea. Grades: 98%. CAS No. 1163719-56-9. Molecular formula: C27H24FN7O3. Mole weight: 513.52. | |
| CCT241161 | This active molecular is a novel , paradox-breaking pan-RAF inhibitor with anti-SRC activity and it blocked growth of BRAF-mutant and NRAS-mutant melanoma cells, inhibiting MEK -ERK. CCT 241161 also prevented growth of xenografts derived from patient tumours with resistance to BRAF and MEK inhibitors. Uses: Effective in drug-resistant braf mutant melanoma. Synonyms: CCT241161; CCT-241161; CCT 241161. 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-(methylthio)-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea. Grades: 98%. CAS No. 1163719-91-2. Molecular formula: C28H27N7O3S. Mole weight: 541.62. | |
| CEP-32496 | CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2. Synonyms: 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea; RXDX-105; RXDX 105; RXDX105; CEP32496; CEP-32496; CEP 32496; AC013773; AC 013773; AC-013773 Agerafenib. Grades: >98%. CAS No. 1188910-76-0. Molecular formula: C24H22F3N5O5. Mole weight: 517.46. | |
| CEP-32496 hydrochloride | CEP-32496, also known as AC013773, is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. CEP-32496 specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Synonyms: CEP-32496; CEP32496; CEP 32496; AC013773; AC 013773; AC-013773. CAS No. 1227678-26-3. Molecular formula: C24H23ClF3N5O5. Mole weight: 553.92. | |
| Claturafenib | Claturafenib ( PF-07799933) is an inhibitor of pan-mutant BRAF. Claturafenib inhibits pERK in HT29 cells with an IC50 value of 1.6 nM[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PF-07799933; ARRY-440. CAS No. 2754408-94-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-159795. | |
| Dabrafenib Mesylate | Dabrafenib, also known as GSK2118436, is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. On May 29, 2013, FDA approved this drug. Synonyms: N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate; Dabrafenib mesylate; GSK 2118436B; GSK2118436B; GSK-2118436B; GSK2118436 Methane sulfonate salt; Brand name: Taflinar. Grades: >98%. CAS No. 1195768-06-9. Molecular formula: C24H24F3N5O5S3. Mole weight: 615.67. | |
| Diazepinomicin | Diazepinomicin, also known as TLN-4601, is a small-molecule inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity. Diazepinomicin binds to and inhibits Ras kinase, thereby preventing the phosphorylation and activation of proteins downstream of the Ras signal transduction pathway, including serine/threonine kinase RAF (BRAF) and extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK-2). This agent also selectively binds to the peripheral benzodiazepine receptor (PBR), a receptor highly expressed in certain tumor cell types cells, inducing cell cycle arrest and apoptosis in PBR-expressing cells. Diazepinomicin can cross the blood-brain barrier (BBB). Synonyms: TLN-4601; TLN 4601; TLN4601; ECO 4601; ECO4601; BU 4664L; ECO 04601; BU4664L; BU-4664L; 4,6,8-trihydroxy-10-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one. CAS No. 733035-26-2. Molecular formula: C28H34N2O4. Mole weight: 462.59. | |
| Encorafenib | Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Synonyms: LGX818; LGX-818; LGX 818; Methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate. Grades: ≥98%. CAS No. 1269440-17-6. Molecular formula: C22H27ClFN7O4S. Mole weight: 540.011. | |
| Encorafenib | Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E ( EC 50 =4 nM). Uses: Scientific research. Group: Signaling pathways. Alternative Names: LGX818. CAS No. 1269440-17-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15605. | |
| Exarafenib | Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity[1][2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: RAF/KIN_2787. CAS No. 2639957-39-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147268. | |
| GDC-0623 | GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM). Uses: Scientific research. Group: Signaling pathways. Alternative Names: RG 7421; MEK inhibitor 1. CAS No. 1168091-68-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15610. | |
| GDC-0879 | GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(V600E) tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS-expressing tumors. Despite the involvement of activated RAF signaling in RAS-induced tumorigenesis, decreased time to progression was observed for some KRAS-mutant tumors following GDC-0879 administration. Moreover, striking differences were noted for RAF and MEK inhibition across a panel of 130 tumor cell lines. Whereas GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type). The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatically altered by pharmacologic and genetic modulation of phosphatidylinositol 3-kinase pathway activity. These data suggest that GDC-0879-induced signaling changes are dependent on the point of oncogenic activation within the RAS network. Taken together, these studies increase our understanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition and have implications for therapeutic intervention in the clinic. Synonyms: GDC0879; GDC-0879; GDC 0879. CAS No. 905281-76-7. Molecular formula: C19H18N4O2. Mole weight: 334.37182. | |
| LEE011 succinate | LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific inhibitor) or BYL719 (a PIK3CA specific inhibitor) leads to robust anti-tumor activity in melanoma and breast cancer tumor models. Synonyms: Ribociclib succinate; LEE 011 succinate; LEE-011 succinate. Grades: >98%. CAS No. 1374639-75-4. Molecular formula: C27H36N8O5. Mole weight: 552.63. | |
| Lifirafenib | Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC 50 values of 23 and 29 nM for recombinant BRaf V600E and EGFR, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BGB-283. CAS No. 1446090-79-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18957. | |
| LY3009120 | LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAF V600E , BRAF WT and CRAF WT with IC 50 s of 5.8, 9.1 and 15 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: DP-4978. CAS No. 1454682-72-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12558. | |
| Malformin A1 | Peptide antibiotic. Antibcaterial. Plant growth stimulator. Induces root curvature and malformation in plants. Mycotoxin. Prevents interleukin-1 (IL-1) induced endothelial changes by inhibition of protein synthesis. Inhibitor of interleukin-1 beta (IL1 beta) binding to its receptor. Enhancer of cellular fibrinolytic activity. Disrupts the cell cycle at the G2 checkpoint of cancer cells, leading to sensitization of the cancer cells to anti-cancer reagents. Anticancer compound. Cytotoxic against several cancer cell lines. Antimalarial and antitrypanosomal. Inhibitor of BRAF-mutated melanoma cell lines. Group: Biochemicals. Grades: Highly Purified. CAS No. 3022-92-2. Pack Sizes: 250ug, 1mg. Molecular Formula: C??H??N?O?S?. US Biological Life Sciences. | Worldwide |
| MK-8353 | MK-8353 is an orally available ERK1/2 inhibitor. It exhibited antitumor activity in patients with BRAFV600-mutant melanoma. Synonyms: (3S)-3-(methylthio)-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxy-3-pyridinyl)-1H-indazol-5-yl]-3-pyrrolidinecarboxamide. CAS No. 1184173-73-6. Molecular formula: C37H41N9O3S. Mole weight: 691.84. | |
| Mono-methyl terephthalate | Mono-methyl terephthalate is used in the synthesis of Hepatits C antiviral activity. Also used in the design and preparation of benzamide derivatives as BRAFV600E inhibitors, which if mutated, can influence malignancies and melanomas. Uses: Mono-methyl terephthalate is used in the synthesis of hepatits c antiviral activity. also used in the design and preparation of benzamide derivatives as brafv600e inhibitors, which if mutated, can influence malignancies and melanomas. Synonyms: MMT; 1,4-Benzenedicarboxylic Acid Monomethyl Ester; Terephthalic Acid Monomethyl Ester; 4-(Carbomethoxy)benzoic Acid; 4-(Methoxycarbonyl)benzoic Acid; 4-[(Methyloxy)carbonyl]benzoic Acid; Hydrogen Methyl Terephthalate; Methyl 4-Carboxybenzoate; Methyl Hydrogen Terephthalate; Methyl p-Carboxybenzoate; Methyl p-Phthalate; Monomethyl terephthalate; NSC 210838; p-(Methoxycarbonyl)benzoic Acid; p-Carbomethoxybenzoic Acid. Grades: 99 % (HPLC). CAS No. 1679-64-7. Molecular formula: C9H8O4. Mole weight: 180.16. | |
| Mosperafenib | BRAF inhibitor. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC)[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: RG6344; RO7276389; B-Raf IN 2. CAS No. 2649372-20-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145120. | |
| Naporafenib | Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC 50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LXH254. CAS No. 1800398-38-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-112089. | |
| Nocodazole | Nocodazole, also called Oncodazole, reversibly inhibits microtubule polymerization so it has anti-neoplastic effect. It is inhibitor of Abl (IC50= 0.21 μM), Abl(E255K) (IC50= 0.53 μM)and Abl(T315I) (IC50= 0.53 μM). in vitro: a high-affinity ligand for Abl phosphorylated (Kd= 0.091 μM), c-Kit (Kd= 1.6 μM), BRAF (Kd= 1.8 μM), and MEK (Kd= 1.6 μM) in vivo: combined with Ketoconazole strongly enhances apoptosis of COLO 205 tumor xenografts. Synonyms: methyl N-[6-(thiophene-2-carbonyl)-1H-benzimidazol-2-yl]carbamate; nocodazole; Oncodazole; 31430-18-9; R 17934; Nocodazolum; Nocidazole; Nocodazol; NSC 238159; Methyl N-(5-thenoyl-2-benzimidazolyl)carbamate; Methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]carbamate; NSC-238159; R-17934; R 17,934; C14H11N3O3S; Methyl 5-(2-thenoyl)-2-benzimidazolecarbamate; Nocodazole [USAN:INN]. CAS No. 31430-18-9. Molecular formula: C14H11N3O3S. Mole weight: 301.32. | |
| Plixorafenib | PLX8394 is a potent and selective BRaf inhibitor, with an IC 50 of appr 5 nM for BRAF V600E. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PLX8394; FORE8394. CAS No. 1393466-87-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18972. | |
| PLX4032 (Vemurafenib) | Vemurafenib selective BRAFV600E kinase inhibitor; an antitumor agent. Vemurafenib functions by inhibiting the proliferation and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and ERK phosphorylation in a panel of tumor cell lines, including melanoma cell lines expressing BRAFV600E or other mutant BRAF proteins altered at codon 600. Group: Biochemicals. Alternative Names: N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide; PLX4032; RG7204; RO51-85426; Zelboraf. Grades: Highly Purified. CAS No. 918504-65-1. Pack Sizes: 500mg, 1g, 2g, 5g, 10g. US Biological Life Sciences. | Worldwide |
| PLX7904 | PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. PB04 is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutant RAS-expressing cells. Synonyms: PLX7904; PLX-7904; PLX 7904; PB04; PB-04; PB 04; paradox-breaker-04. Grades: 98%. CAS No. 1393465-84-3. Molecular formula: C24H22F2N6O3S. Mole weight: 512.54. | |
| PLX7904 | PLX7904 is a potent and selective BRAF inhibitor, with IC50 of appr 5 nM against BRAFV600E in mutant RAS expressing cells. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PB04. CAS No. 1393465-84-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18997. | |
| Rafoxanide | Rafoxanide is a poent, orally active halogenated salicylaniline agent with antiparasitic activity. Rafoxanide interferes with energy metabolism in trematodes by uncoupling oxidative phosphorylation. Rafoxanide is also found to be a potent inhibitor of the BRAF V600E mutant protein , which is important in colorectal cancer. Rafoxanide can be used for the control of infestation with Hemonchus species or Fasciola species in sheep and cattle as well as Oestrus ovis in sheep. Rafoxanide can also be used for cancer research [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 22662-39-1. Pack Sizes: 10 mM * 1 mL; 500 mg; 1 g; 5 g; 10 g. Product ID: HY-17598. | |
| RMC-4550 | RMC-4550 is a potent and selective SHP-2 inhibitor with IC50 value of 1.55 nM. It inhibits RAS/MAPK signaling in cancer cell lines with Class 3 BRAF mutations. Synonyms: RMC 4550; RMC4550. CAS No. 2172651-73-7. Molecular formula: C21H26Cl2N4O2. Mole weight: 437.36. | |
| SCH772984 | SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 942183-80-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-50846. | |
| SCH772984 | SCH772984 is a potent and selective ERK inhibitor with potential anticancer activity. SCH722984 showed activity against BRAF mutant, NRAS mutant and wild-type melanoma. Combining vemurafenib and SCH722984 in BRAF mutant melanoma was synergistic in a majority of cell lines and significantly delayed the onset of acquired resistance in long term in vitro assays. Therefore, SCH772984 may be clinically applicable as a treatment for non-BRAF mutant melanoma or in BRAF-mutant melanoma with innate or acquired resistance, alone or in combination with BRAF inhibitors. Synonyms: SCH-772984; SCH 772984; (R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-yl)pyrrolidine-3-carboxamide. Grades: 95%. CAS No. 942183-80-4. Molecular formula: C33H33N9O2. Mole weight: 587.688. | |
| Sorafenib, p-Toluenesulfonate Salt | Sorafenib (Bay 43-9006) is a novel bi-aryl urea compound that inhibits cell proliferation by targeting the ERK pathway and angiogenesis by targeting the receptor tyrosine kinases VEGFR-2 and PDGFR-b and their associated signaling cascades. Although sorafenib was initially developed as a Raf kinase inhibitor (IC50=6nM), it has since been shown to have activity against many receptor tyrosine kinases involved in tumorigenesis and angiogenesis including FGFR-1, wt BRAF and V599E mutant BRAF, as well as members of the so-called "split kinase" family: VEGFR-2, VEGFR-3, PDGFR-b, c-KIT, and Flt3. However, sorafenib is not active against erbB1, erbB2, ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-MET, c-yes, PKB, PKA, cdk1/cyclinB, PKC, and pim-1. In cellular mechanistic assays, sorafenib decreased basal phosphorylation of the ERK pathway in melanoma, breast, colon, and pancreatic tumor cell lines. Group: Biochemicals. Grades: Highly Purified. CAS No. 475207-59-1. Pack Sizes: 1g, 5g, 10g. Molecular Formula: C21H16ClF3N4O3 C7H8O3S, Molecular Weight: 637.03. US Biological Life Sciences. | Worldwide |
| TAK-632 | TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50 value of 2.4 nM. Synonyms: TAK632, TAK 632, TAK-632. CAS No. 1228591-30-7. Molecular formula: C27H18F4N4O3S. Mole weight: 554.51. | |
| TAK-632 | TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1228591-30-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15767. | |
| Temuterkib | Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LY3214996. CAS No. 1951483-29-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101494. | |
| Trametinib | A MEK inhibitor that suppresses MEK1 and MEK2 with IC50 of 0.92 and 1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. It has been approved by FDA, in combination with Tafilnar, for the treatment of metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation. Synonyms: GSK-1120212; GSK 1120212; GSK1120212; JTP74057; JTP 74057; JTP-74057; Mekinist. Grades: ≥98%. CAS No. 871700-17-3. Molecular formula: C26H23FIN5O4. Mole weight: 615.39. | |
| Uplarafenib | Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC 50 between 50 and 100 nM. Uplarafenib shows antitumor activity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: B-Raf IN 10. CAS No. 1425485-87-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148059. | |
| Vemurafenib-Analog | BRAF inhibitor is a potent BRAF inhibitor. Synonyms: 2-Propanesulfonamide, N-[2,4-difluoro-3-[[5-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]phenyl]-. Grades: >98%. CAS No. 918505-61-0. Molecular formula: C22H18F2N4O3S. Mole weight: 456.47. | |
| Vemurafenib, Free Base (PLX4032) | Vemurafenib selective BRAFV600E kinase inhibitor; an antitumor agent. Vemurafenib functions by inhibiting the proliferation and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and ERK phosphorylation in a panel of tumor cell lines, including melanoma cell lines expressing BRAFV600E or other mutant BRAF proteins altered at codon 600. Group: Biochemicals. Alternative Names: N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide; PLX4032; RG7204; RO51-85426; Zelboraf. Grades: Highly Purified. CAS No. 918504-65-1. Pack Sizes: 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
